EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cogent Biosciences's Enterprise Value is $653.88 Mil.
Cogent Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-208.36 Mil. Therefore, Cogent Biosciences's EV-to-FCF for today is -3.14.
The historical rank and industry rank for Cogent Biosciences's EV-to-FCF or its related term are showing as below:
COGT'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.64 Med: -4.19 Max: 0.55
Current: -3.14
During the past 10 years, the highest EV-to-FCF of Cogent Biosciences was 0.55. The lowest was -13.64. And the median was -4.19.
COGT's EV-to-FCF is ranked worse than 100% of 416
companies
in the Biotechnology industry
Industry Median: 3.79
vs COGT: -3.14
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Cogent Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cogent Biosciences's EV-to-FCF
For the Biotechnology subindustry, Cogent Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's EV-to-FCF falls into.
Cogent Biosciences's current Enterprise Value is $653.88 Mil.
Cogent Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-208.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cogent Biosciences's PE Ratio (TTM) for today is calculated as:
Cogent Biosciences's share price for today is $7.39.
Cogent Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.465.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cogent Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Cogent Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COGT has been successfully added to your 